Back to top
more

Corcept Therapeutics (CORT)

(Delayed Data from NSDQ)

$72.56 USD

72.56
650,568

+0.04 (0.06%)

Updated Oct 27, 2025 04:00 PM ET

After-Market: $73.55 +0.99 (1.36%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.81%
2Buy17.98%
3Hold9.90%
4Sell5.43%
5Strong Sell2.74%
S&P50011.32%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (79 out of 243)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Why Corcept Therapeutics (CORT) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Is Corcept Therapeutics (CORT) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Corcept Therapeutics (CORT) and Delcath Systems, Inc. (DCTH) have performed compared to their sector so far this year.

Zacks Equity Research

CORT's Q4 Earnings and Revenues Fall Short of Estimates

by Zacks Equity Research

Corcept reports weaker-than-expected results for the fourth quarter of 2024. Korlym drives year-over-year sales.

Zacks Equity Research

Why Corcept Therapeutics (CORT) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Is Janus Henderson Small Cap Growth Alpha ETF (JSML) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for JSML

Zacks Equity Research

Corcept Therapeutics (CORT) Q4 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Corcept (CORT) delivered earnings and revenue surprises of -29.73% and 7.08%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Should Janus Henderson Small Cap Growth Alpha ETF (JSML) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for JSML

Zacks Equity Research

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FBT

Zacks Equity Research

Is Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF (GSSC) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for GSSC

Zacks Equity Research

Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol

by Zacks Equity Research

Corcept, Amneal, Dyne, Nektar and Cardiol have been highlighted in this Industry Outlook article.

Zacks Equity Research

Corcept (CORT) Soars 13.6%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Corcept (CORT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Kinjel Shah headshot

5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era

by Kinjel Shah

Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, DYN, NKTR and CRDL may prove to be good additions to one's portfolio.

Zacks Equity Research

Should Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF (GSSC) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for GSSC

Zacks Equity Research

Zacks.com featured highlights include OppFi, Corcept Therapeutics, DXP Enterprises, Perpetua Resources and Graham

by Zacks Equity Research

OppFi, Corcept Therapeutics, DXP Enterprises, Perpetua Resources and Graham are part of the Zacks Screen of the Week article.

Zacks Equity Research

All You Need to Know About Corcept (CORT) Rating Upgrade to Strong Buy

by Zacks Equity Research

Corcept (CORT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Nalak Das headshot

Buy These 5 Stocks With Recent Price Strength Amid a Volatile January

by Nalak Das

Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are OPFI, CORT, DXPE, PPTA, GHM.

Zacks Equity Research

Is Corcept (CORT) a Solid Growth Stock? 3 Reasons to Think "Yes"

by Zacks Equity Research

Corcept (CORT) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Equity Research

Corcept Therapeutics Incorporated (CORT) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Corcept (CORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Here's What Could Help Corcept (CORT) Maintain Its Recent Price Strength

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, Corcept (CORT) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Zacks Equity Research

Corcept Submits Application for Another Cushing's Syndrome Drug

by Zacks Equity Research

CORT makes pipeline progress with the submission of a new drug application for relacorilant to treat patients with endogenous hypercortisolism.

Zacks Equity Research

Should Janus Henderson Small Cap Growth Alpha ETF (JSML) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for JSML

Zacks Equity Research

Is Janus Henderson Small Cap Growth Alpha ETF (JSML) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for JSML

Zacks Equity Research

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FBT

Zacks Equity Research

CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study

by Zacks Equity Research

The phase II DAZALS study evaluating Corcept's dazucorilant in patients with amyotrophic lateral sclerosis fails to meet the primary goal.

Zacks Equity Research

Here's Why Corcept Therapeutics (CORT) is a Strong Momentum Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.